<p>Stem cells reside in specialized microenvironments, termed niches, at several different locations in tissues<sup><CitationRef AdditionalCitationIDS="CR2" CitationID="CR1">1</CitationRef>–<CitationRef CitationID="CR3">3</CitationRef></sup>. The differential functions of heterogeneous stem cells and niches are important given the increasing clinical applications of stem-cell transplantation and immunotherapy. Whether hierarchical structures among stem cells at distinct niches exist and further control aspects of immune tolerance is unknown. Here we describe previously unknown new hierarchical arrangements in haematopoietic stem cells (HSCs) and bone marrow niches that dictate both regenerative potential and immune privilege. High-level nitric oxide-generating (NO<sup>hi</sup>) HSCs are refractory to immune attack and exhibit delayed albeit robust long-term reconstitution. Such highly immune-privileged, primitive NO<sup>hi</sup> HSCs co-localize with distinctive capillaries characterized by primary ciliated endothelium and high levels of the immune-checkpoint molecule CD200. These capillaries regulate the regenerative functions of NO<sup>hi</sup> HSCs through the ciliary protein IFT20 together with CD200, endothelial nitric oxide synthase and autophagy signals, which further mediate immunoprotection. Notably, previously described niche constituents, sinusoidal cells and type-H vessels<sup><CitationRef AdditionalCitationIDS="CR3 CR4 CR5 CR6 CR7 CR8 CR9" CitationID="CR2">2</CitationRef>–<CitationRef CitationID="CR10">10</CitationRef></sup> co-localize with less immune-privileged and less potent NO<sup>low</sup> HSCs. Together, we identify highly immune-privileged, late-rising primitive HSCs and characterize their immunoprotective niches comprising specialized vascular domains. Our results indicate that the niche orchestrates hierarchy in stem cells and immune tolerance, and highlight future immunotherapeutic targets.</p>

错误:搜索内容不能为空,请输入英文关键词
错误:关键词超出字数限制,请精简
高级检索

Bone marrow niches orchestrate stem-cell hierarchy and immune tolerance

  • Kazuhiro Furuhashi,
  • Miwako Kakiuchi,
  • Ryosuke Ueda,
  • Hiroko Oda,
  • Simone Ummarino,
  • Alexander K. Ebralidze,
  • Mahmoud A. Bassal,
  • Chen Meng,
  • Tatsuyuki Sato,
  • Jing Lyu,
  • Min-guk Han,
  • Shoichi Maruyama,
  • Yu Watanabe,
  • Yuriko Sawa,
  • Daisuke Kato,
  • Hiroaki Wake,
  • Boris Reizis,
  • John A. Frangos,
  • David M. Owens,
  • Daniel G. Tenen,
  • Ionita C. Ghiran,
  • Simon C. Robson,
  • Joji Fujisaki

摘要

Stem cells reside in specialized microenvironments, termed niches, at several different locations in tissues13. The differential functions of heterogeneous stem cells and niches are important given the increasing clinical applications of stem-cell transplantation and immunotherapy. Whether hierarchical structures among stem cells at distinct niches exist and further control aspects of immune tolerance is unknown. Here we describe previously unknown new hierarchical arrangements in haematopoietic stem cells (HSCs) and bone marrow niches that dictate both regenerative potential and immune privilege. High-level nitric oxide-generating (NOhi) HSCs are refractory to immune attack and exhibit delayed albeit robust long-term reconstitution. Such highly immune-privileged, primitive NOhi HSCs co-localize with distinctive capillaries characterized by primary ciliated endothelium and high levels of the immune-checkpoint molecule CD200. These capillaries regulate the regenerative functions of NOhi HSCs through the ciliary protein IFT20 together with CD200, endothelial nitric oxide synthase and autophagy signals, which further mediate immunoprotection. Notably, previously described niche constituents, sinusoidal cells and type-H vessels210 co-localize with less immune-privileged and less potent NOlow HSCs. Together, we identify highly immune-privileged, late-rising primitive HSCs and characterize their immunoprotective niches comprising specialized vascular domains. Our results indicate that the niche orchestrates hierarchy in stem cells and immune tolerance, and highlight future immunotherapeutic targets.